Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T63178
|
|||||
| Target Name |
Melanoma-associated antigen 10 (MAGEA10)
|
|||||
| Synonyms |
Cancer/testis antigen 1.10; CT1.10; MAGE-10 antigen
Click to Show/Hide
|
|||||
| Gene Name |
MAGEA10
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 4 Target-related Diseases | + | ||||
| 1 | Bladder cancer [ICD-11: 2C94] | |||||
| 2 | Head and neck cancer [ICD-11: 2D42] | |||||
| 3 | Melanoma [ICD-11: 2C30] | |||||
| 4 | Non-small-cell lung cancer [ICD-11: 2C25] | |||||
| Function |
Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| Sequence |
MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPSSFPSSSSSSS
SSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDEGSSSQKEESPSTL QVLPDSESLPRSEIDEKVTDLVQFLLFKYQMKEPITKAEILESVIRNYEDHFPLLFSEAS ECMLLVFGIDVKEVDPTGHSFVLVTSLGLTYDGMLSDVQSMPKTGILILILSIVFIEGYC TPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWVQENYLEYRQVPGSDPARYEFLWGP RAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDEEERAQDRIATTDDTTAMASASSS ATGSFSYPE Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | ADP-A2M10 | Drug Info | Phase 1 | Bladder cancer | [2] | |
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581. | |||||
| REF 2 | Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.